EVMN Evommune Inc

Price (delayed)

$8.77

Market cap

$318.28M

P/E Ratio

1.58

Dividend/share

N/A

EPS

$5.54

Enterprise value

$265.16M

?
Relative Growth: Rel. Growth: 48
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 79
Relative Profitability: Rel. Profitability: 27

Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The company's mission is to improve patients' daily lives and prevent the ...

Highlights
The company's EPS has surged by 113% YoY
The company's debt fell by 5% QoQ
Evommune's quick ratio has decreased by 42% from the previous quarter but it has increased by 34% YoY
EVMN's net income is down by 46% YoY and by 25% from the previous quarter
Evommune's equity has decreased by 9% QoQ

Key stats

What are the main financial stats of EVMN

EVMN stock price

How has the Evommune stock price performed over time
Intraday
-8.65%
1 week
-6.4%
1 month
-37.45%
1 year
N/A
YTD
-48.77%
QTD
-34.01%

Financial performance

How have Evommune's revenue and profit performed over time
Revenue
$10M
Gross profit
$10M
Operating income
-$101.89M
Net income
-$94.67M
Gross margin
100%
Net margin
-946.7%
EVMN's operating margin has surged by 60% year-on-year but it is down by 13% since the previous quarter
The company's net margin has surged by 56% YoY but it fell by 25% QoQ
EVMN's net income is down by 46% YoY and by 25% from the previous quarter
Evommune's operating income has decreased by 34% YoY and by 13% from the previous quarter

Price vs fundamentals

How does EVMN's price correlate with its fundamentals

Growth

What is Evommune's growth rate over time

Valuation

What is Evommune stock price valuation
P/E
1.58
P/B
1.14
P/S
31.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.52
The company's EPS has surged by 113% YoY
Evommune's equity has decreased by 9% QoQ

Efficiency

How efficient is Evommune business performance
EVMN's return on invested capital has surged by 80% year-on-year and by 12% since the previous quarter
The ROE has soared by 68% from the previous quarter
The company's return on sales has surged by 56% YoY but it fell by 25% QoQ
The ROA has grown by 41% YoY and by 2.9% from the previous quarter

Dividends

What is EVMN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EVMN.

Financial health

How did Evommune financials performed over time
EVMN's total liabilities has surged by 133% year-on-year and by 36% since the previous quarter
EVMN's current ratio is down by 43% since the previous quarter but it is up by 24% year-on-year
The company's debt is 97% lower than its equity
Evommune's equity has decreased by 9% QoQ
The company's debt fell by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.